Earth Science Tech, Inc. (OTC: ETST) this morning reported that it has finalized preparations for its nine-month human trial to evaluate the effectiveness of a blend of broad-spectrum cannabinoid industrial hemp oil and essential mineral element. The trial seeks to develop a CBD formulation for the treatment of opioid addicts, relieving withdrawal symptoms, and averting fatal overdoses. ETST aims to increase the potency of its formulation by combining its full-spectrum cannabinoids industrial hemp oil with essential minerals. The trial is scheduled to be completed in 2019 and it will be supervised by ETST chief learning officer Gabriel Aviles and CEO Dr. Michel Aube. Per the update, ETST is prepared to manufacture and introduce new products in the market to combat the current scourge of opioid deaths in America if the formulation proves successful. ETST is currently collaborating with CGMP laboratory to mix the anti-opioid formula for the human trials, and it is in talk with rehabilitation centers that are interested in participating in the project.
To view the full press release, visit http://ibn.fm/cQtrb
About Earth Science Tech, Inc.
Earth Science Tech has among the highest quality, purity and full-spectrum high-grade hemp CBD (cannabidiol) oil on the market. Made using the superior supercritical CO2 liquid extraction, ETST’s CBD oil is 100% natural and organic. The company’s research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrates that ETST is the top nutritional and dietary supplement brand for high-grade hemp CBD oil. To learn more and to buy CBD Hemp Oil, please visit: www.EarthScienceTech.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
